doi:10.1002/pmic.200800989
Some patients report losing 1-2 pounds per week when combined with a structured plan

Assuming that the percentage of patients showing an increase in serum vitamin B12 concentration to above 179 pg/ml in both groups is 70%, means the study requires at least 304 patients (152 in each arm) for a threshold of non-inferiority of 10% and a statistical power of 60% with significance set at p 179 pg/ml: patient preference questionnaire Randomisation of patients to treatment group Visit 1 (start of treatment) Anamnesis: record whether the patient lives alone or with others, lifestyle habits, use of alcohol, whether a vegan diet is followed, whether the patient has undergone gastrectomy Symptoms: record paresthesia, asthenia, loss or reduction of appetite, sadness or change in state of mind, concomitant pharmacological treatment Physical examination: for Hunters glositis, positional and vibrational sensitivity Questionnaires: Lobo cognitive mini-exam, EuroQoL-5D Record concomitant treatment Request analyses to be performed one week before next visit: haemogram and serum vitamin B12 Therapeutic plan: patient in oral arm provision of medication

Use a refrigerator thermometer to verify your storage temperature
Vitamin B12 injections begin working almost immediately at a cellular level, though the timeframe for noticeable symptom improvement varies considerably between individuals
BPC-157 (5mg-10mg), Body Protection Compound 157 A Pentadecapeptide of Gastric Origin Introduction A Pentadecapeptide of Gastric Origin BPC-157 is a synthetic 15-residue peptide derived from a partial sequence identified within a larger gastric protective protein originally isolated from human gastric juice in the mid-1990s by Sikiric and colleagues at the University of Zagreb